Pilot Study of 89-Zr Panitumumab in Pancreas Cancer
Trial ID or NCT#
NCT04833959
Status
NOT RECRUITING
Purpose
The main purpose of the study is to assess the safety of 89Zr-panitumumab as a molecular imaging agent in patients with (metastatic) pancreas cancer.
Official Title
Pilot Study of 89Zr Panitumumab in Pancreas Cancer
Eligibility Criteria
Ages Eligible for Study: Older than 19 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Inclusion Criteria:
- - Confirmed diagnosis of pancreatic cancer.
Exclusion Criteria:
- - Myocardial infarction (MI); cerebrovascular accident (CVA); uncontrolled congestive heart failure (CHF); significant liver disease; or unstable angina within 6 months prior to enrollment. - History of infusion reactions to monoclonal antibody therapies. - Pregnant or breastfeeding. - Subjects receiving Class IA (quinidine, procainamide) or Class III (dofetilide, amiodarone, sotalol) antiarrhythmic agents. - Subjects with a history or evidence of interstitial pneumonitis or pulmonary fibrosis. - Severe renal disease or anuria. - Known hypersensitivity to deferoxamine or any of its components.
Investigator(s)
George A. Poultsides, MD, MS
Hepatobiliary surgeon,
Pancreatic surgeon,
Liver surgeon,
Sarcoma specialist,
Gastrointestinal specialist,
Minimally invasive surgeon
Professor of Surgery (General Surgery) at the Stanford University Medical Center
George A. Fisher Jr.
Medical oncologist,
Gastrointestinal specialist
Colleen Haas Chair in the School of Medicine
Contact us to find out if this trial is right for you.
Contact
Alexander A Valencia
650-498-5185
View on ClinicalTrials.gov
